SCM
FHTX icon

SCS Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

SCS Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$522K Hold
106,980
– – ﹤0.01% 358
2026
Q1 		$511K Hold
106,980
– – 0.01% 349
2025
Q4 		$578K Hold
106,980
– – 0.01% 348
2025
Q3 		$523K Hold
106,980
– – 0.01% 376
2025
Q2 		$503K Hold
106,980
– – 0.01% 388
2025
Q1 		$390K Buy
+106,980
New +$488K 0.01% 395

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

SCS Capital Management's FHTX Position: Q2 2026 in Review

SCS Capital Management held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 106,980 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #358.

SCS Capital Management first reported a position in FHTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $578K in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • SCS Capital Management held 106,980 shares of Foghorn Therapeutics worth $522K as of Q2 2026.
  • SCS Capital Management left its Foghorn Therapeutics share count unchanged in Q2 2026.
  • Foghorn Therapeutics made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #358 holding.
  • SCS Capital Management first reported a position in Foghorn Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's Foghorn Therapeutics position peaked at $578K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.